(SOBI) Swedish Orphan Biovitrum - Ratings and Ratios

Swedish Orphan Biovitrum AB (publ) is a biopharmaceutical company that specializes in developing and commercializing medicines for rare diseases, operating across multiple regions including Europe, North America, the Middle East, Asia, and Australia. The companys diverse portfolio is organized into three business segments: Haematology, Immunology, and Specialty Care, addressing a range of serious and rare medical conditions.

The companys product portfolio includes a range of treatments for haemophilia A and B, paroxysmal nocturnal haemoglobinuria, immune thrombocytopenia, and other rare conditions. Notable products include Alprolix, ALTUVOCT, Aspaveli/Empaveli, Doptelet, Elocta/Eloctate, Gamifant, Kineret, Orfadin, Synagis, VONJO, and Zynlonta. Additionally, Sobi provides other medicines such as Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra, and develops drug substances for Pfizers ReFacto AF/Xyntha.

Sobi has established collaboration agreements with major pharmaceutical companies, including Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc., to further expand its pipeline and commercial opportunities. With a history dating back to 1939, the company is headquartered in Stockholm, Sweden, and is listed on the Stockholm Stock Exchange.

Analyzing the companys and , we can observe that SOBIs stock has been trading around its 50-day moving average (286.60) and is currently below its 20-day moving average (300.43) and 200-day moving average (308.02). The Average True Range (ATR) indicates a moderate level of volatility. The stocks price is near the lower end of its 52-week range, suggesting potential for growth. With a Market Cap of 101457.19M SEK and a P/E ratio of 25.82, the company is valued at a premium. However, the forward P/E ratio of 21.01 suggests expected earnings growth. The Return on Equity (RoE) of 9.08 indicates a relatively stable profitability.

Based on the analysis of and , a forecast for SOBI could be as follows: Given the current trading price and the technical indicators, we can expect a potential short-term correction or consolidation. However, considering the companys diversified product portfolio, established collaborations, and expected earnings growth, we can anticipate a long-term upward trend. A potential price target could be around 320-330 SEK, representing a 9-12% increase from the current price. Nonetheless, this forecast is subject to various market and economic factors, and it is essential to continuously monitor the companys performance and adjust the forecast accordingly.